REGN Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Company profile
Ticker
REGN
Exchange
Website
CEO
Leonard Schleifer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
REGENERON PHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
133444607
REGN stock data
()
News
Regeneron Highlights Updated NIH COVID-19 Guidelines, Which 'Strongly Recommend' REGEN-COV Be Used In Non-Hospitalized Patients
9 Apr 21
The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
3 Apr 21
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
2 Apr 21
The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO
31 Mar 21
Cathie Wood's ARK Invest Posts Fund Sales For Tuesday, Mar. 30, 2021: TCEHY, TREE, NVS, PHR, SYRS, ICE, SPOT, REGN, PYPL, PCAR, ISRG, API, FB
30 Mar 21
Press releases
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression
9 Apr 21
Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021
6 Apr 21
NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
30 Mar 21
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
25 Mar 21
Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
23 Mar 21
Calendar
8 Feb 21
11 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Feb 21 | Vagelos P Roy | Common Stock | Payment of exercise | Dispose F | No | No | 458.48 | 137,998 | 63.27M | 349,090 |
23 Feb 21 | Vagelos P Roy | Common Stock | Option exercise | Aquire M | No | No | 52.03 | 248,079 | 12.91M | 487,088 |
23 Feb 21 | Vagelos P Roy | Common Stock | Option exercise | Aquire M | No | No | 52.03 | 1,921 | 99.95K | 239,009 |
23 Feb 21 | Vagelos P Roy | NQSO Common Stock | Option exercise | Dispose M | No | No | 52.03 | 248,079 | 12.91M | 0 |
23 Feb 21 | Vagelos P Roy | Incentive Stock Option Common Stock | Option exercise | Dispose M | No | No | 52.03 | 1,921 | 99.95K | 0 |
17 Feb 21 | Regeneron Pharmaceuticals | Common Stock | Conversion | Aquire C | No | No | 0 | 2,097,314 | 0 | 2,097,314 |
17 Feb 21 | Regeneron Pharmaceuticals | Series C Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 14,000,000 | 0 | 0 |
17 Feb 21 | Regeneron Pharmaceuticals | Series B Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 12,500,000 | 0 | 0 |
1 Feb 21 | Ryan Arthur F | Common Stock | Sell | Dispose S | No | Yes | 512.82 | 2 | 1.03K | 23,691 |
1 Feb 21 | Ryan Arthur F | Common Stock | Sell | Dispose S | No | Yes | 509.28 | 4 | 2.04K | 23,693 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
85.9% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 861 |
Opened positions | 135 |
Closed positions | 141 |
Increased positions | 355 |
Reduced positions | 269 |
13F shares |
Current |
---|---|
Total value | 43.7B |
Total shares | 90.41M |
Total puts | 2.47M |
Total calls | 1.82M |
Total put/call ratio | 1.4 |
Largest owners |
Shares | Value |
---|---|---|
FMR | 11.48M | $5.55B |
BLK Blackrock | 9.78M | $4.72B |
Vanguard | 7.93M | $3.83B |
Capital World Investors | 6.95M | $3.36B |
STT State Street | 4.69M | $2.27B |
Wellington Management | 3.63M | $1.75B |
Loomis Sayles & Co L P | 2.96M | $1.43B |
JPM JPMorgan Chase & Co. | 2.31M | $1.12B |
Polen Capital Management | 2M | $967.58M |
Alliancebernstein | 1.76M | $851.89M |
Financial report summary
?Competition
Novelion Therapeutics • Biocryst Pharmaceuticals • IRIDEX • Seagen • Cytokinetics • Achillion Pharmaceuticals • Curis • Macrogenics • Molecular Templates • Intersect ENTRisks
- Our business may be further adversely affected by the effects of the COVID-19 pandemic.
- We face risks related to the development, manufacturing, and commercialization of REGEN-COV.
- We are substantially dependent on the success of EYLEA and Dupixent.
- If we or our collaborators are unable to continue to successfully commercialize our products, our business, prospects, operating results, and financial condition will be materially harmed.
- We and our collaborators are subject to significant ongoing regulatory obligations and oversight with respect to the products we or our collaborators commercialize. If we or our collaborators fail to maintain regulatory compliance for any of such products, the applicable marketing approval may be withdrawn, which would materially harm our business, prospects, operating results, and financial condition.
- Sales of our marketed products are dependent on the availability and extent of reimbursement from third-party payors, and changes to such reimbursement may materially harm our business, prospects, operating results, and financial condition.
- The commercial success of our products and product candidates is subject to significant competition.
- We rely on our collaborations with Bayer and Sanofi for commercializing some of our marketed products.
- Sales of our marketed products recorded by us and our collaborators could be reduced by imports from countries where such products may be available at lower prices.
- We may be unsuccessful in continuing the commercialization of our marketed products or in commercializing our product candidates or new indications for our marketed products, if approved, which would materially and adversely affect our business, profitability, and future prospects.
- We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of or significant reduction in sales to these customers would adversely affect our results of operations.
- If we are unable to establish commercial capabilities outside the United States for products we intend to commercialize or co-commercialize outside the United States, our business, prospects, operating results, and financial condition may be adversely affected.
- If we or our collaborators do not maintain regulatory approval for our marketed products, and obtain regulatory approval for our product candidates or new indications for our marketed products, we will not be able to market or sell them, which would materially and negatively impact our business, prospects, operating results, and financial condition.
- Obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.
- Preclinical and clinical studies required for our product candidates and new indications of our marketed products are expensive and time-consuming, and their outcome is highly uncertain. If any such studies are delayed or yield unfavorable results, regulatory approval for our product candidates or new indications of our marketed products may be delayed or become unobtainable.
- Successful development of our current and future product candidates is uncertain.
- Serious complications or side effects in connection with the use of our products and in clinical trials for our product candidates and new indications for our marketed products could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products, which could severely harm our business, prospects, operating results, and financial condition.
- Our product candidates in development are recombinant proteins that could cause an immune response, resulting in the creation of harmful or neutralizing antibodies against the therapeutic protein.
- We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale, which could materially harm our business, prospects, operating results, and financial condition.
- Many of our products are intended to be used and, if approved, our product candidates may be used in combination with drug-delivery devices, which may result in additional regulatory, commercialization, and other risks.
- If we cannot protect the confidentiality of our trade secrets, or our patents or other means of defending our intellectual property are insufficient to protect our proprietary rights, our business and competitive position will be harmed.
- We may be restricted in our development, manufacturing, and/or commercialization activities by patents or other proprietary rights of others, and could be subject to awards of damages if we are found to have infringed such patents or rights.
- Loss or limitation of patent rights, and regulatory pathways for biosimilar competition, could reduce the duration of market exclusivity for our products.
- We rely on limited internal and contracted manufacturing and supply chain capacity, which could adversely affect our ability to commercialize our marketed products and, if approved, our product candidates and to advance our clinical pipeline.
- Expanding our manufacturing capacity and establishing fill/finish capabilities will be costly and we may be unsuccessful in doing so in a timely manner, which could delay or prevent the launch and successful commercialization of our marketed products and product candidates or other indications for our marketed products if they are approved for marketing and could jeopardize our current and future clinical development programs.
- Our ability to manufacture products may be impaired if any of our or our collaborators' manufacturing activities, or the activities of other third parties involved in our manufacture and supply chain, are found to infringe patents of others.
- If sales of our marketed products do not meet the levels currently expected, or if the launch of any of our product candidates is delayed or unsuccessful, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.
- Third-party service or supply failures, or other failures, business interruptions, or other disasters affecting our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, the manufacturing facilities of our collaborators, or the facilities of any other party participating in the supply chain, would adversely affect our ability to supply our products.
- Our or our collaborators' failure to meet the stringent requirements of governmental regulation in the manufacture of drug products or product candidates could result in incurring substantial remedial costs, delays in the development or approval of our product candidates or new indications for our marketed products and/or in their commercial launch if regulatory approval is obtained, and a reduction in sales.
- If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.
- Our business activities have been, and may in the future be, challenged under federal or state healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.
- Our operations are subject to environmental, health, and safety laws and regulations, including those governing the use of hazardous materials. Compliance with these laws and regulations is costly, and we may incur substantial liability arising from our activities involving the use of hazardous materials.
- Our business is subject to increasingly complex corporate governance, public disclosure, and accounting requirements and regulations that could adversely affect our business, operating results, and financial condition.
- Changes in laws and regulations affecting the healthcare industry could adversely affect our business.
- Risks associated with our operations outside of the United States could adversely affect our business.
- We may incur additional tax liabilities related to our operations.
- We face potential liability related to the personal information we collect from individuals, data brokers, or research institutions or obtain from clinical trials sponsored by us or our collaborators.
- Increasing use of social media could give rise to liability, breaches of data security, or reputational damage.
- If our Antibody Collaboration or our IO Collaboration with Sanofi is terminated, our business, prospects, operating results, and financial condition, and our ability to develop, manufacture, and commercialize certain of our products and product candidates in the time expected, or at all, would be materially harmed.
- If our collaboration with Bayer for EYLEA is terminated, or Bayer materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition, and our ability to continue to commercialize EYLEA outside the United States would be materially harmed.
- Our collaborators and service providers may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and current and future products.
- We are dependent on our key personnel and if we cannot recruit and retain leaders in our research, development, manufacturing, and commercial organizations, our business will be harmed.
- Significant disruptions of information technology systems or breaches of data security could adversely affect our business.
- If we cannot sustain profitability, our business, prospects, operating results, and financial condition would be materially harmed.
- We may need additional funding in the future, which may not be available to us, and which may force us to delay, reduce or eliminate our product development programs or commercialization efforts.
- Our indebtedness could adversely impact our business.
- Changes in foreign currency exchange rates could have a material adverse effect on our operating results.
- Our investments are subject to risks and other external factors that may result in losses or affect the liquidity of these investments.
- The elimination of LIBOR could adversely affect our business, operating results, and financial condition.
- Our stock price is extremely volatile.
- Future sales of our Common Stock by our significant shareholders or us may depress our stock price and impair our ability to raise funds in new share offerings.
- There can be no assurance that we will repurchase shares of our Common Stock or that we will repurchase shares at favorable prices.
- Our existing shareholders may be able to exert substantial influence over matters requiring shareholder approval and over our management.
- The anti-takeover effects of provisions of our charter, by-laws, and of New York corporate law, as well as the contractual provisions in our investor and collaboration agreements and certain provisions of our compensation plans and agreements, could deter, delay, or prevent an acquisition or other "change of control" of us and could adversely affect the price of our Common Stock.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
adherence, ADR, aforementioned, Aimmune, AKS, Allele, allergen, alleviate, antitrust, approach, arisen, arm, array, asymptomatic, atoltivimab, awaiting, belonging, Biden, bioresearch, birch, Black, bond, bore, career, carefully, casirivimab, certified, child, chosen, closure, coaching, cogent, Colorado, Commonwealth, complimenting, conclusive, confirmatory, constantly, contamination, costimulatory, counterclaim, countermeasure, credible, CRS, crucial, curtailment, Deficiency, denominator, diagnose, DIRA, disapprove, distancing, driven, dyslipidemia, economy, edited, EEA, EHS, elder, elongation, emotional, empowered, engraftment, enjoined, Enlarged, enteropathy, ergonomic, escape, ESMO, essential, ethnic, ethnicity, EUA, Evkeeza, EvkeezaTM, exact, extortion, facilitate, fatal, Female, flexibility, flexible, forbidding, formal, Fortune, foster, fostering, fungal, futility, gather, geographic, gift, GITR, globe, guide, heightened, heightening, hemophilia, Hereditary, homegrown, Hong, hour, household, housemate, Iceland, imdevimab, immunodeficient, impede, indemnity, Inmazeb, InmazebTM, insert, intake, intervention, IRB, ITC, itepekimab, job, join, justifying, Jyseleca, kg, Kong, Lab, Labour, leader, leadership, leaseback, leave, Leqvio, Liechtenstein, lifted, Macau, maftivimab, magnitude, main, mainland, Mayo, meditation, mental, mentally, MFN, microbial, mission, movement, mutant, myasthenia, NEJM, Neoadjuvant, nephropathy, NIAID, NIH, NMPA, Northern, Norway, notified, nurse, odronextamab, omalizumab, online, onsite, ordinary, organizational, outlining, outreach, outweigh, overage, Overnight, oversee, overturned, Oxford, oxygen, pandemic, passive, pause, pausing, PBM, PFS, pharmacovigilance, philosophy, PIP, pollen, postponement, predetermined, prioritization, proceed, proud, prurigo, PSMF, PSU, pulse, purity, QPPV, quarantine, question, race, racial, Racketeer, ransomware, recession, recipient, recoup, redeem, redeemed, remote, repaid, repay, repeatedly, representation, restraining, resume, retention, Rinat, rollout, room, seronegative, shelter, Sherman, SOFR, Solicitor, sooner, spike, spread, spring, steering, strain, strength, surveillance, survey, symptomatic, talent, Tariff, transthyretin, treble, trend, TTR, tuition, UCLA, UHC, unacceptable, underage, underpinning, underrepresented, uninfected, UnitedHealthcare, University, upside, urgency, urgent, vaccination, vaccine, VelociHum, ventilation, Vetter, video, virology, Virtual, volunteerism, warning, weighing, wellbeing, whistleblower, willfully, Women, workforce, workplace, worn, Wuhan, Zai, Zaire
Removed:
AbbVie, accommodate, acute, afflicted, analyzing, appoint, basal, Biogen, category, ceased, cGCP, clarification, closely, comprise, concomitant, conspiracy, constitute, consultant, consummated, consummation, daily, deductibility, define, deny, deployed, destination, Directive, diverse, elevated, evidenced, execute, exhausted, expensing, FOB, foundational, freight, functional, genotyping, guaranteed, highest, intent, kind, modulate, municipal, Nordisk, novelty, Novo, pcJIA, predecessor, preserving, proportionately, proposal, recommending, refractory, remained, renovated, repeal, repealing, stipulate, sum, sustaining, taxation, tender, Threshold, toxicology, treaty, Trump, underwriter, underwritten, Unlimited, vi, waive
Financial reports
10-K
2020 FY
Annual report
8 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
7 Feb 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
7 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
Current reports
8-K
Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
5 Feb 21
8-K
Entry into a Material Definitive Agreement
15 Jan 21
8-K
Results of Operations and Financial Condition
11 Jan 21
8-K
Departure of Directors or Certain Officers
5 Jan 21
8-K
Regeneron Reports Third Quarter 2020 Financial and Operating Results
5 Nov 20
8-K
Entry into a Material Definitive Agreement
19 Aug 20
8-K
Entry into a Material Definitive Agreement
12 Aug 20
8-K
Regeneron Reports Second Quarter 2020 Financial and Operating Results
5 Aug 20
8-K
Entry into a Material Definitive Agreement
7 Jul 20
8-K
Departure of Directors or Certain Officers
16 Jun 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
10 Aug 20
FWP
Free writing prospectus
7 Aug 20
424B3
Prospectus supplement
7 Aug 20
S-8
Registration of securities for employees
16 Jun 20
424B3
Prospectus supplement
28 May 20
424B3
Prospectus supplement
26 May 20
FWP
Free writing prospectus
26 May 20
FWP
Free writing prospectus
26 May 20
S-3ASR
Automatic shelf registration
13 Nov 18
S-8
Registration of securities for employees
11 Jun 17
Proxies
DEFA14A
Additional proxy soliciting materials
8 Jun 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
DEFA14A
Additional proxy soliciting materials
22 Apr 18
DEF 14A
Definitive proxy
22 Apr 18
DEFA14A
Additional proxy soliciting materials
22 Apr 18
Other
UPLOAD
Letter from SEC
3 Jan 21
CORRESP
Correspondence with SEC
6 Dec 20
UPLOAD
Letter from SEC
19 Nov 20
CT ORDER
Confidential treatment order
15 Jul 20
CT ORDER
Confidential treatment order
8 Oct 19
CT ORDER
Confidential treatment order
14 May 19
CT ORDER
Confidential treatment order
9 May 19
CT ORDER
Confidential treatment order
7 May 19
CT ORDER
Confidential treatment order
26 Jul 18
CT ORDER
Confidential treatment order
8 Jan 18
Ownership
4
REGENERON PHARMACEUTICALS / P ROY VAGELOS ownership change
24 Feb 21
4
Change in insider ownership
18 Feb 21
SC 13G/A
REGENERON PHARMACEUTICALS / Capital World Investors ownership change
16 Feb 21
3
Initial statement of insider ownership
11 Feb 21
SC 13G/A
REGENERON PHARMACEUTICALS / VANGUARD ownership change
10 Feb 21
SC 13G/A
REGENERON PHARMACEUTICALS / FMR ownership change
8 Feb 21
4
REGENERON PHARMACEUTICALS / ARTHUR F RYAN ownership change
2 Feb 21
SC 13G/A
REGENERON PHARMACEUTICALS / BlackRock ownership change
1 Feb 21
4
REGENERON PHARMACEUTICALS / MICHAEL S BROWN ownership change
27 Jan 21
4
REGENERON PHARMACEUTICALS / MICHAEL S BROWN ownership change
5 Jan 21
Patents
APP
Utility
CRNN Loss of Function Rodent Model
8 Apr 21
This disclosure relates to a genetically modified rodent and use thereof as a rodent model.
APP
Utility
Genetically Modified Non-human Animals and Methods of Use Thereof
8 Apr 21
Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease.
APP
Utility
Non-Human Animals Expressing Humanized CD3 Complex
8 Apr 21
Non-human animals, expressing humanized CD3 proteins are provided.
APP
Utility
Methods for Reducing or Eliminating the Need for Lipoprotein Apheresis In Patients with Hyperlipidemia by Administering Alirocumab
8 Apr 21
The present invention provides methods for reducing or eliminating a patient's need for lipoprotein apheresis therapy.
APP
Utility
High Affinity Human Antibodies to Human Angiopoietin-2
8 Apr 21
The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same.
Transcripts
2020 Q4
Earnings call transcript
5 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
5 May 20
2019 Q4
Earnings call transcript
6 Feb 20
2019 Q3
Earnings call transcript
5 Nov 19
2019 Q2
Earnings call transcript
6 Aug 19
2019 Q1
Earnings call transcript
7 May 19
2018 Q4
Earnings call transcript
6 Feb 19
2018 Q3
Earnings call transcript
6 Nov 18
Reddit threads
If you had $10000 what would you spend it on?
9 Apr 21
For Those Owning 30+ Stocks - Why?
8 Apr 21
Favorite non-tech stocks?
7 Apr 21
CRSP Crispr DNA editor
7 Apr 21
Long term stocks
4 Apr 21
Here is a Market Recap for today Thursday, April 1, 2021
1 Apr 21
Here is a Market Recap for today Thursday, April 1, 2021
1 Apr 21
Pacific Biosciences of California (PACB) DD
31 Mar 21
What are your best value stock investments at current prices
28 Mar 21
Where are you at on Biotech?
28 Mar 21